查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008665

反義RNAi療法市場：依寡核苷酸類型、給藥途徑、治療領域和最終用戶分類－全球市場預測（2026-2032年）

Antisense & RNAi Therapeutics Market by Oligonucleotide Type, Mode Of Administration, Therapeutic Areas, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，反義 RNAi 療法市場價值將達到 54.6 億美元，到 2026 年將成長至 62.5 億美元，到 2032 年將達到 152.3 億美元，複合年成長率為 15.76%。

主要市場統計數據
預測年份（2025年） 54.6億美元
基準年（2026 年） 62.5億美元
預測年份（2032年） 152.3億美元
複合年成長率（） 15.76%

將分子層面的創新與反義 RNAi 療法的臨床預期聯繫起來，以重新定義治療範式、遞送方法和患者結果。

反義和干擾RNA（RNAi）療法正從小眾科學研究走向主流治療方法，影響多個治療領域和臨床策略。過去十年，化學、遞送平台和監管科學的進步，使從分子概念到臨床概念驗證，最終到核准產品的路徑更加清晰。因此，從小規模專業生技公司到大規模綜合製藥公司，許多相關人員將寡核苷酸平台視為解決以往無法治療標靶的核心資產。相應地，研發團隊目前正努力在早期創新與實際需求（例如生產規模、安全性評估和以病人為中心的給藥方案）之間取得平衡。

平台成熟度、監管澄清和協作營運模式正在重塑反義 RNAi 產品的開發和商業化途徑。

反義RNAi療法領域正經歷著一場變革，其驅動力包括平台成熟、監管政策的明確性以及更廣泛的臨床應用目標的整合。平台成熟體現在兩個方面：化學方法和結合策略的進步提高了藥物的穩定性和療效，而遞送技術的創新則拓展了藥物作用於肝臟以外其他組織的途徑。這些技術進步降低了標靶選擇的傳統障礙，使得藥物研發計畫能夠優先考慮患者的便利性和長期用藥依從性。因此，藥物研發人員正擴大探索心血管疾病、代謝性疾病和神經退化性疾病等適應症，而這些疾病先前被認為在技術上或商業性不可行。

本研究評估了美國在 2025 年採取的關稅措施對寡核苷酸療法的原料採購、製造物流和全球供應的影響。

2025年關稅措施所營造的政策環境將對寡核苷酸價值鏈產生重大影響，該價值鏈涉及原料採購、特殊試劑和關鍵耗材的跨境貿易。關稅若增加進口核苷酸、修飾亞磷醯胺、脂質體配方用脂質以及某些酵素的成本，可能會即時給製造商帶來成本壓力，影響其擴大生產規模和選擇商業生產基地的決策。從長遠來看，持續存在的貿易壁壘可能會進一步促進供應鏈本地化，並鼓勵對國內或近岸生產能力進行投資，以降低進口價格波動帶來的風險。

細分市場洞察顯示寡核苷酸類型、給藥途徑、治療標靶和最終用戶如何影響研發重點和商業化選擇。

細分市場分析能夠清楚展現科學機會與商業性可行性的交集，而理解這些細分市場對於確定投資優先順序和製定商業策略至關重要。根據寡核苷酸的類型，此領域可分為反義寡核苷酸和干擾性RNAi（RNAi）。在干擾性RNAi領域，該計畫可進一步細分為微干擾RNA（microIFR）和小干擾RNA（siRNA），二者各自具有獨特的效力、劑量假設和遞送方式。這些分子差異會影響計畫層面的化學性質、結合策略和毒性監測的選擇，以及目標組織選擇和生物標記策略的發展。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢正在影響研發地點、生產製造、監管和病患取得途徑。

區域趨勢對研發策略、製造地和市場拓展計畫產生了顯著影響，導致不同區域形成了各自獨特的產能叢集。在美洲，密集的生物技術生態系統和先進的臨床基礎設施支援快速概念驗證（PoC）試驗，並推動生產網路的擴張，優先考慮可擴展性和監管合規性。這些條件使該地區成為後期研發和商業化推出的理想之地。同時，創業投資和公共資金的持續湧入也推動了平台技術和First-in-Class項目的創新。

平衡競爭與合作的企業策略：透過合作與平台投資加速產品線成長，擴大 RNA 療法的生產規模。

寡核苷酸領域的企業發展趨勢反映了競爭與合作之間的平衡，策略聯盟和平台投資推動了研發管線的加速和生產規模的擴大。該領域的領導企業正投資於化學創新、偶聯技術以及遞送系統，例如脂質載體和受體靶向偶聯物，以擴大其在各機構的覆蓋範圍並提高安全性。這些投資輔以精心挑選的併購和合作活動，將藥物發現能力與後期開發和商業化資源結合。

為產業領導者提供切實可行的策略行動，以最佳化反義RNAi療法的交付，降低開發風險，並加速臨床部署。

產業領導企業可以採納一系列優先且切實可行的建議，以增強其反義RNAi計畫的韌性並加速價值實現。首先，在藥物發現過程的早期階段就應考慮遞送和CMC（化學、生產和品管）因素，以確保平台選擇符合可生產性、監管要求和患者用藥偏好。早期對化學和製劑進行協同最佳化可以減少後期返工，並縮短實現可重複且可擴展生產的路徑。其次，透過供應商網路多元化和認證取代原料來源來降低供應鏈風險。應將受關稅影響的原料和關鍵試劑的情境規劃納入採購和專案風險登記冊。

清晰的調查方法概述了應用於反義 RNAi 療法分析的一級和二級調查、專家訪談和數據三角測量。

本分析採用混合方法研究，結合一手質性研究結果和嚴謹的二手資料，建構了一個以證據為基礎的敘述。主要資料來源包括對藥物研發、CMC、臨床營運和商業化等領域的專家進行的結構化訪談，這些訪談提供了有關營運挑戰、技術應用曲線和策略重點的背景資訊。除這些訪談外，還與生產負責人和法規事務專家進行了有針對性的討論，以確保為規模化生產的實際問題和合規要求提供切實可行的支援。

一份簡潔、全面的分析報告，重點介紹了推動反義 RNAi 療法發展的相關人員所面臨的策略挑戰、關鍵問題和可操作的途徑。

本文提出的綜合分析凸顯了該領域正處於轉折點的現狀。儘管平台和遞送方式的創新正在拓展反義RNAi療法的臨床應用，但也增加了商業性和營運的複雜性。關鍵挑戰包括平台選擇和可製造性匹配、建立能夠應對貿易和關稅不確定性的彈性供應鏈，以及設計能夠滿足支付方和醫療服務提供者循證需求的臨床項目。具備科學抱負、嚴謹的營運執行力和策略夥伴關係關係的相關人員，將更有能力將技術進步轉化為對病患和企業都永續的成果。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章：反義RNAi療法市場：以寡核苷酸類型分類

  • 反義寡核苷酸
  • 干擾RNAi
    • 微干擾RNA
    • 小干擾RNA

第9章：反義RNAi療法市場：依給藥途徑分類

  • 鞘內腔
  • 靜脈
  • 口服
  • 皮下
  • 外用

第10章：反義RNAi治療市場：依治療領域分類

  • 循環系統
  • 免疫學
  • 代謝性疾病
  • 神經系統疾病
  • 瘤
  • 眼科
  • 罕見疾病

第11章 反義RNAi療法市場：以最終用戶分類

  • CRO（委外研發機構）
  • 製藥公司
  • 研究機構

第12章 反義RNAi療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 反義RNAi療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 反義RNAi療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國反義RNAi療法市場

第16章：中國反義RNAi療法市場

第17章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • Acuitas Therapeutics Inc.
  • Alloy Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Benitec Biopharma Limited
  • City Therapeutics
  • Danaher Corporation
  • Eli Lilly and Company
  • Evox Therapeutics Ltd
  • GenScript Biotech Corporation
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Ribocure Pharmaceuticals AB
  • Sanofi SA
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Stoke Therapeutics, Inc.
  • Suzhou Ribo Life Science Co., Ltd.
  • Wave Life Sciences Ltd
Product Code: MRR-8E22B61932A7

The Antisense & RNAi Therapeutics Market was valued at USD 5.46 billion in 2025 and is projected to grow to USD 6.25 billion in 2026, with a CAGR of 15.76%, reaching USD 15.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.46 billion
Estimated Year [2026] USD 6.25 billion
Forecast Year [2032] USD 15.23 billion
CAGR (%) 15.76%

Bridging molecular innovation and clinical promise in antisense and RNAi therapeutics to redefine treatment paradigms, delivery, and patient outcomes

Antisense and RNA interference (RNAi) therapeutics are transitioning from a niche scientific pursuit into a mainstream modality influencing multiple therapeutic areas and clinical strategies. Over the past decade, advances in chemistry, delivery platforms, and regulatory science have brought a clearer line of sight from molecular concept to clinical proof of concept, and increasingly to approved products. As a result, stakeholders ranging from small specialized biotechs to large, integrated pharmaceutical companies view oligonucleotide platforms as core assets for addressing previously intractable targets. Consequently, development teams are now balancing early-stage innovation with the practicalities of manufacturing scale, safety characterization, and patient-centric administration.

At the same time, clinical programs are diversifying. Research now extends beyond rare genetic diseases into more prevalent therapeutic segments where modulation of gene expression offers differentiated mechanisms of action. This expansion has been enabled by technologies that improve tissue targeting, reduce off-target effects, and enable lower dosing frequencies, thereby strengthening the clinical and commercial rationale for antisense oligonucleotides and RNAi agents. Further, improvements in analytical methods and preclinical models have increased confidence in translational choices, enabling a faster, more iterative path from bench to clinic.

Importantly, the evolving landscape requires integrated thinking: scientific innovation must be matched by supply chain resilience, regulatory engagement, and payer-forward evidence generation. As development cycles compress and regulatory pathways become better-understood, program teams must orchestrate cross-functional alignment early and execute with heightened operational rigor. This introduction sets the stage for a deeper exploration of the transformative shifts reshaping the field, the policy and trade dynamics that affect global supply chains, and the practical segmentation and regional nuances leaders must account for when designing portfolios and commercialization strategies.

Platform maturation regulatory clarity and collaborative operational models that are reshaping antisense and RNAi product development and commercialization pathways

The antisense and RNAi therapeutic landscape is undergoing transformative shifts driven by convergence of platform maturation, regulatory clarity, and broader clinical ambition. Platform maturation has been twofold: chemistry and conjugate strategies have improved stability and potency, while delivery innovations have extended reach into tissues beyond the liver. These technical advances have reduced historical barriers to target selection and enabled programs that prioritize patient convenience and long-term adherence. As a result, drug developers are increasingly exploring indications in cardiovascular, metabolic, and neurodegenerative diseases that were previously considered technically or commercially infeasible.

Regulatory pathways are also adapting, with agencies demonstrating greater familiarity with oligonucleotide-specific risks and benefit profiles. This familiarity permits more predictable interactions around nonclinical packages, biomarker strategy, and safety monitoring, which, in turn, shortens the cycle from early human trials to pivotal studies. In parallel, clinical trial design is becoming more adaptive and biomarker-driven, supporting enriched patient selection and clearer demonstration of mechanism. Consequently, sponsors are leveraging translational endpoints and real-world evidence frameworks to build payer-relevant dossiers earlier in development.

Commercial and operational behaviors are aligning with these scientific and regulatory shifts. Developers are prioritizing manufacturing scalability and advanced analytics to de-risk CMC activities, while partnerships and alliances link clinical capabilities with specialized contract development and manufacturing organizations. These collaborative structures enable smaller sponsors to retain strategic control of their science while accessing the industrial capabilities necessary to move programs through late-stage development and into the market. Taken together, these shifts are expanding the definition of clinical viability and redefining strategic playbooks across research, development, and commercialization.

Evaluating how 2025 US tariff actions could reshape raw material sourcing, manufacturing logistics, and global supply of oligonucleotide therapeutics

The policy environment created by tariff measures in 2025 has important implications for the oligonucleotide value chain, where raw material sourcing, specialized reagents, and critical consumables traverse international borders. Tariffs that raise the cost of imported nucleotides, modified phosphoramidites, lipids used in lipid nanoparticle formulations, and select enzymes could create immediate cost pressure for manufacturers and impact decisions about where to site process scale-up and commercial production. Over time, sustained trade barriers can encourage greater regionalization of supply chains and foster investment in domestic or nearshore production capacity to mitigate exposure to import volatility.

Operationally, higher import costs will often translate into longer procurement lead times as buyers consolidate orders to achieve scale or requalify multiple suppliers for redundancy. In turn, this behavior places a premium on supplier relationship management, quality oversight, and inventory policies. For sponsors and contract manufacturers, the strategic response may include securing multi-year contracts, investing in alternate chemistries that reduce reliance on tariff-exposed inputs, or accelerating vertical integration strategies where feasible. Regulatory timelines for process changes must also be considered, as re-sourcing critical raw materials can require additional process validation and regulatory communications, potentially constraining the flexibility of clinical supply strategies.

Strategically, tariff-induced shifts can yield both challenge and opportunity. While cost increases present near-term headwinds, they can motivate investments in domestic manufacturing capacity, regional talent development, and improved process efficiencies that strengthen long-term supply resilience. Moreover, policy uncertainty typically increases the value of diversified sourcing and robust risk management programs. Consequently, organizations that proactively model tariff scenarios, incorporate contingency options into procurement and manufacturing plans, and engage with policy stakeholders where appropriate will be better positioned to maintain development momentum despite trade disruptions.

Segmentation insights demonstrating how oligonucleotide type, administration mode, therapeutic targets, and end users shape R&D focus and commercialization choices

Segmentation analysis provides clarity on where scientific opportunity and commercial viability intersect, and understanding these segments is critical for prioritizing investment and operational design. Based on Oligonucleotide Type, the landscape differentiates antisense oligonucleotides and interfering RNAi; within interfering RNAi, programs further distinguish between micro interfering RNAs and small interfering RNAs, each with distinct potency, dosing expectations, and delivery considerations. These molecular distinctions drive program-level choices in chemistry, conjugation strategies, and toxicity monitoring, and also inform the selection of tissue targets and biomarker strategies.

Based on Mode Of Administration, development paths and patient adoption profiles diverge significantly across intrathecal, intravenous, oral, subcutaneous, and topical routes. Administration mode influences formulation science, cold chain and logistics requirements, and the design of clinical operations; for example, intrathecal and intravenous routes often necessitate facility-based administration and more complex safety monitoring, while subcutaneous and oral options support decentralized models that can improve patient retention and real-world uptake. As a result, companies must weigh the trade-offs between clinical efficacy, patient convenience, and the downstream implications for reimbursement and market access.

Based on Therapeutic Areas, program portfolios reflect a breadth of indication choices, spanning cardiovascular, immunology, metabolic disorders, neurological disorders, oncology, ophthalmology, and rare diseases. Each therapeutic area carries unique regulatory expectations, clinical endpoint challenges, and competitive dynamics. For instance, neurology and rare disease programs may rely heavily on validated biomarkers and patient registries, whereas oncology and cardiovascular initiatives may require larger, event-driven trials and differentiated value propositions for payers. Strategic alignment between therapeutic focus and platform strengths is therefore a core determinant of program design and resource allocation.

Based on End User, the market's ecosystem includes contract research organizations, pharmaceutical companies, and research laboratories that collectively shape innovation cycles and commercialization pathways. Contract research organizations play an increasingly central role in providing specialized development and manufacturing capabilities that lower barriers for sponsors. Pharmaceutical companies contribute commercial scale, regulatory expertise, and payer engagement capabilities, while research laboratories drive early discovery and mechanistic understanding. The interplay among these end users determines how capabilities are assembled, how risks are shared, and how innovations ultimately reach patients.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping development hubs, manufacturing, regulations, and patient access

Regional dynamics exert outsized influence on development strategies, manufacturing footprints, and go-to-market planning, with distinct capability clusters emerging across geographies. In the Americas, dense biotech ecosystems and advanced clinical infrastructure support rapid proof-of-concept studies and growing manufacturing networks that prioritize scale and regulatory familiarity. These conditions make the region attractive for late-stage development and commercial launches, while access to venture and public capital continues to drive innovation in platform technologies and first-in-class programs.

In Europe, Middle East & Africa, a mix of academic excellence, regulatory harmonization within certain jurisdictions, and evolving industrial policy encourages partnerships and center-of-excellence models. Sponsors targeting these markets often coordinate multi-jurisdictional regulatory strategies and leverage regional manufacturing hubs to serve multiple neighboring markets efficiently. Policy incentives and public-private collaborations in parts of this region also encourage investment in capacity expansion and advanced analytics.

Across Asia-Pacific, capacity expansion, government-supported industrial initiatives, and a rapidly maturing clinical research environment are reshaping supply and demand dynamics. Increasing local manufacturing capabilities and talent pools create opportunities for nearshore sourcing and regional clinical acceleration. Consequently, many organizations are evaluating hybrid development models that combine western clinical development with Asia-Pacific manufacturing or clinical execution to optimize timelines, cost, and patient recruitment. Taken together, these regional patterns underscore the importance of aligning portfolio design with geographic strengths to optimize development velocity and commercial access.

Competitive and collaborative company strategies alliances and platform investments accelerating pipelines and scaling manufacturing for RNA-based therapies

Company behaviors in the oligonucleotide sector reflect a balance of competition and collaboration, with strategic alliances and platform investments driving acceleration of pipelines and scaling of manufacturing. Leaders in the space are investing in chemistry innovations, conjugate technologies, and delivery systems such as lipid-based carriers or receptor-targeting conjugates to expand tissue reach and improve safety margins. These investments are complemented by selective M&A and partnership activity that brings together discovery capabilities with late-stage development and commercialization resources.

Beyond scientific investments, companies are making deliberate choices about how to structure manufacturing operations. Some sponsors opt to partner with specialized contract development and manufacturing organizations to access scale quickly, while others pursue vertically integrated models to retain greater control over critical process steps and supply security. In either case, investments in analytical capabilities, process automation, and regulatory-ready quality systems are common priorities, as they materially reduce the time and risk associated with scale-up and commercial release.

Collaboration extends to payer and provider engagement as well. Forward-looking companies are modeling long-term value propositions that incorporate dosing convenience, durability of effect, and real-world outcomes to build evidence packages that resonate with health systems. Partnerships that align clinical development with payer expectations and delivery systems enhance the probability of favorable access conditions and smoother rollout strategies. Overall, corporate strategies emphasize platform differentiation, manufacturing resilience, and cross-sector engagement to convert scientific potential into durable clinical and commercial success.

Practical strategic actions for industry leaders to optimize delivery, de-risk development, and accelerate clinical adoption of antisense and RNAi therapies

Industry leaders can pursue a set of prioritized, actionable recommendations to enhance resilience and accelerate value realization across antisense and RNAi programs. First, integrate delivery and CMC considerations early in the discovery process so that platform choices align with manufacturability, regulatory expectations, and patient administration preferences. Early co-optimization of chemistry and formulation reduces late-stage rework and shortens the path to reproducible, scalable manufacturing. Second, diversify supplier networks and qualify alternate raw material sources to mitigate supply chain risk; scenario planning for tariff-impacted inputs and critical reagents should be embedded into procurement and program risk registers.

Third, pursue collaborative models that leverage specialized CDMOs and research partners to access capacity and technical expertise without overextending capital deployment. Strategic alliances that include shared development milestones and de-risking mechanisms can accelerate timelines while preserving upside for original innovators. Fourth, design clinical programs with payer-relevant endpoints and real-world evidence components that anticipate market access questions earlier in development; this alignment increases the probability of reimbursement and supports broader adoption post-launch. Fifth, invest in regulatory strategy and proactive engagement with authorities to clarify expectations around nonclinical safety, biomarker qualification, and comparability as manufacturing scales. Proactive regulatory planning reduces uncertainty and supports more efficient submission packages.

Finally, prioritize workforce capability building and cross-functional governance to manage complex development portfolios effectively. Establish multidisciplinary teams that align discovery, translational science, CMC, clinical operations, and commercial planning to ensure decisions are made with a holistic view of program risks and opportunities. Collectively, these actions create a practical roadmap for leaders seeking to translate molecular promise into patient impact while controlling development complexity and commercial risk.

Clear research methodology outlining primary and secondary approaches expert interviews and data triangulation applied to antisense and RNAi therapeutic analysis

This analysis is grounded in a mixed-methods research approach that combines primary qualitative insights and rigorous secondary synthesis to create an evidence-based narrative. Primary inputs include structured interviews with subject-matter experts across discovery, CMC, clinical operations, and commercial functions, which offer context on operational challenges, technology adoption curves, and strategic priorities. These conversations were supplemented by targeted consultations with manufacturing leaders and regulatory affairs specialists to ensure practical grounding in scale-up realities and compliance expectations.

Secondary research entailed systematic review of peer-reviewed literature, regulatory guidance documents, public company disclosures, and technical white papers that illuminate technology advances, safety considerations, and clinical trends. Data from diverse sources were triangulated to identify consistent signals, reconcile differences, and highlight areas of emerging consensus or uncertainty. Throughout the process, findings were validated against expert perspectives to refine interpretation, ensure factual accuracy, and surface actionable implications for decision-makers.

Concise synthesis highlighting strategic imperatives key challenges and practical pathways for stakeholders advancing antisense and RNAi therapeutic development

The synthesis presented here underscores a sector at an inflection point: platform and delivery innovations are broadening the clinical applicability of antisense and RNAi modalities even as commercial and operational complexities increase. Key imperatives include aligning platform choices with manufacturability, building resilient supply chains that account for trade and tariff uncertainty, and designing clinical programs that address payer and provider evidence needs. Stakeholders who combine scientific ambition with disciplined operational execution and strategic partnerships will be best positioned to convert technical advances into durable patient and commercial outcomes.

Persistent challenges remain, including tissue-specific delivery beyond canonical targets, long-term safety characterization, and the logistical demands of scalable manufacturing. Nonetheless, by prioritizing early alignment across discovery, CMC, and clinical functions and by proactively managing external risks such as trade policy shifts, organizations can navigate the complexity and capture the value this therapeutic class offers. The conclusion is pragmatic: success will favor those who pair innovation with operational foresight and market-oriented evidence generation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type

  • 8.1. Antisense Oligonucleotides
  • 8.2. Interfering RNAi
    • 8.2.1. Micro Interfering RNAs
    • 8.2.2. Small Interfering RNAs

9. Antisense & RNAi Therapeutics Market, by Mode Of Administration

  • 9.1. Intrathecal
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous
  • 9.5. Topical

10. Antisense & RNAi Therapeutics Market, by Therapeutic Areas

  • 10.1. Cardiovascular
  • 10.2. Immunology
  • 10.3. Metabolic Disorders
  • 10.4. Neurological Disorders
  • 10.5. Oncology
  • 10.6. Ophthalmology
  • 10.7. Rare Diseases

11. Antisense & RNAi Therapeutics Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Pharmaceutical Companies
  • 11.3. Research Laboratories

12. Antisense & RNAi Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antisense & RNAi Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antisense & RNAi Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antisense & RNAi Therapeutics Market

16. China Antisense & RNAi Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Acuitas Therapeutics Inc.
  • 17.6. Alloy Therapeutics, Inc.
  • 17.7. Alnylam Pharmaceuticals, Inc.
  • 17.8. Arbutus Biopharma Corporation
  • 17.9. Arrowhead Pharmaceuticals, Inc.
  • 17.10. AstraZeneca plc
  • 17.11. Bayer AG
  • 17.12. Benitec Biopharma Limited
  • 17.13. City Therapeutics
  • 17.14. Danaher Corporation
  • 17.15. Eli Lilly and Company
  • 17.16. Evox Therapeutics Ltd
  • 17.17. GenScript Biotech Corporation
  • 17.18. GSK PLC
  • 17.19. Ionis Pharmaceuticals, Inc.
  • 17.20. Merck KGaA
  • 17.21. Novo Nordisk A/S
  • 17.22. Pfizer Inc.
  • 17.23. Ribocure Pharmaceuticals AB
  • 17.24. Sanofi S.A.
  • 17.25. Shanghai Argo Biopharmaceutical Co., Ltd.
  • 17.26. Silence Therapeutics plc
  • 17.27. Stoke Therapeutics, Inc.
  • 17.28. Suzhou Ribo Life Science Co., Ltd.
  • 17.29. Wave Life Sciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 123. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)